3-Oct-2024
CYC Signs Agreement with VA and First DoD Order Received
1-Oct-2024
Change of Director's Interest Notice - JW
3-Sep-2024
Cyclopharm - 2024 First Half Results & USA Expansion Update
29-Aug-2024
Webinar - 1H2024 Results and USA update
27-Aug-2024
Cyclopharm 2024 H1 Trading and USA Expansion Update
28-Jun-2024
Cleansing Notice
28-Jun-2024
Application for quotation of securities - CYC
28-Jun-2024
Proposed issue of securities - CYC
28-Jun-2024
Change of Director's Interest Notice - KB
28-Jun-2024
Change of Director's Interest Notice - DH
28-Jun-2024
Change of Director's Interest Notice - DA
28-Jun-2024
Application for quotation of securities - CYC
27-Jun-2024
Appendix 3B
27-Jun-2024
Update - Proposed issue of securities - CYC
25-Jun-2024
Update - Proposed issue of securities - CYC
25-Jun-2024
Cyclopharm completes oversubscribed Share Purchase Plan
24-Jun-2024
USA Reimbursement Update for TECHNEGAS
19-Jun-2024
Cyclopharm Presenting at Macquarie Emerging Leaders Conf
11-Jun-2024
Change in substantial holding AACCF
11-Jun-2024
Change in substantial holding Chemical Overseas
11-Jun-2024
Change in substantial holding Barings
5-Jun-2024
Change in substantial holding from CVC
5-Jun-2024
TECHNEGAS Awarded US Pass-Through Reimbursemt Status
4-Jun-2024
Cleansing Statement - Placement
4-Jun-2024
Update - Application for quotation of securities - CYC
4-Jun-2024
CYC Results of AGM Poll - Addendum
3-Jun-2024
Change of Director's Interest Notice - GK
3-Jun-2024
Change in substantial holding
31-May-2024
Share Purchase Plan Offer Booklet
30-May-2024
Update - Application for quotation of securities - CYC
30-May-2024
Cleasing Statement - Placement
29-May-2024
Change of Director's Interest Notice - JW
29-May-2024
Application for quotation of securities - CYC
29-May-2024
CYC Results of AGM poll amended
27-May-2024
Notification of buy-back - CYC
27-May-2024
CYC Results of AGM poll
27-May-2024
Update - Proposed issue of securities - CYC
27-May-2024
Managing Director's AGM address
27-May-2024
CYC 2024 AGM Presentation
27-May-2024
Chairman's Address to Shareholders
27-May-2024
Cyclopharm Successfully Completes A$20.0 Million Placement
24-May-2024
Proposed issue of securities - CYC
24-May-2024
Cyclopharm Capital Raising
24-May-2024
Cyclopharm Capital Raising Presentation
24-May-2024
Trading Halt
16-May-2024
Appendix 3C Final buy-back notification
6-May-2024
Cyclopharm Business Update
26-Apr-2024
Becoming a substantial holder
26-Apr-2024
Notice of Annual General Meeting/Proxy Form
24-Apr-2024
Ceasing to be a substantial holder
8-Apr-2024
Application for quotation of securities - CYC
26-Mar-2024
Appendix 4G
25-Mar-2024
Voluntary Escrow Shares to be Released
25-Mar-2024
Date of Annual General Meeting
19-Mar-2024
First USA Patients Imaged with Technegas
1-Mar-2024
S&P DJI Announces March 2024 Quarterly Rebalance
19-Feb-2024
CYC Board Changes
19-Feb-2024
Initial Director's Interest Notice
12-Feb-2024
Cyclopharm Appoints Jason Smith as CFO
6-Feb-2024
Cyclopharm to Present at Euroz Hartleys Healthcare Forum
5-Feb-2024
Cyclopharm Trading and USA Launch Update
29-Jan-2024
CYC and Yale Translational Research Partner on Technegas
5-Dec-2023
Cyclopharm Signs First USA Contract for Technegas
1-Dec-2023
Change of Director's Interest Notice
1-Dec-2023
Application for quotation of securities - CYC
15-Nov-2023
Technegas USA Commercialisation Update
2-Nov-2023
Change of Director's Interest Notice
1-Nov-2023
Change of Director's Interest Notice
5-Oct-2023
CYC USFDA Approval Webinar Presentation
3-Oct-2023
FDA Technegas Approval Webinar
3-Oct-2023
SNMMI Announcement Regarding USFDA Approval of Technegas
2-Oct-2023
Cyclopharm Receives USFDA Approval for Technegas
26-Sep-2023
Cyclopharm Investor Update
26-Sep-2023
Investor Presentation Correction
26-Sep-2023
Investor Presentation Correction
12-Sep-2023
Application for quotation of securities - CYC
25-Aug-2023
Litigation Update and Receipt of Settlement Payment
22-Aug-2023
Dividend/Distribution - CYC
9-Aug-2023
USFDA Approval Process Update
17-Jul-2023
Cyclopharm 2023 Half Year Accounts Update - Record Revenues
16-May-2023
Notification of buy-back - CYC
16-May-2023
Results of Meeting
16-May-2023
Managing Director's Address to Shareholders
16-May-2023
CYC 2023 AGM Presentation
16-May-2023
Chairman's Address to Shareholders
9-May-2023
Cyclopharm Confirms USFDA Scheduled Inspection Date
24-Apr-2023
USFDA Confirms Technegas Six Month Review Period
20-Apr-2023
Cyclopharm Acquires DuPharma ApS
18-Apr-2023
Application for quotation of securities - CYC
17-Apr-2023
Proposed issue of securities - CYC
13-Apr-2023
Notice of Annual General Meeting/Proxy Form
5-Apr-2023
Cyclopharm USFDA Approval Progress Update
31-Mar-2023
Appendix 4G
30-Mar-2023
Technegas Enters Final Six Month USFDA Review Cycle
24-Mar-2023
Application for quotation of securities - CYC
15-Mar-2023
Date of Annual General Meeting
20-Feb-2023
Dividend/Distribution - CYC
5-Dec-2022
Change of Director's Interest Notice - KBarrow
30-Nov-2022
Change of Director's Interest Notice - DAngus
9-Nov-2022
Bell Potter Healthcare Conference Directors Profile
9-Nov-2022
Bell Potter Healthcare Conference
5-Oct-2022
Notification of cessation of securities - CYC
27-Sep-2022
CYC Board Changes
27-Sep-2022
Initial Director's Interest Notice
1-Sep-2022
Initial Director's Interest Notice
1-Sep-2022
CYC Board Changes
17-Aug-2022
Dividend/Distribution - CYC
7-Jul-2022
Technegas Used In Multicenter COVID Study
4-Jul-2022
1H 2022 Business Update - Record Revenues
14-Jun-2022
Change of Director's Interest Notice
24-May-2022
CYC Investor Presentation 24 May 2022
24-May-2022
Technegas used in Diagnosing Long COVID
23-May-2022
Change of Director's Interest Notice
17-May-2022
Results of Meeting
17-May-2022
Managing Director's Address to Shareholders
17-May-2022
CYC 2022 AGM Presentation
17-May-2022
Chairman's Address to Shareholders
14-Apr-2022
Notice of Annual General Meeting/Proxy Form
31-Mar-2022
Appendix 4G
16-Mar-2022
Date of Annual General Meeting
9-Mar-2022
Change of Director's Interest Notice
4-Mar-2022
S&P DJI Announces March 2022 Quarterly Rebalance
23-Feb-2022
Dividend/Distribution - CYC
3-Feb-2022
Cyclopharm USFDA Update
1-Dec-2021
Final Director's Interest Notice
1-Dec-2021
Board Update
9-Nov-2021
Bell Potter HealthCare Conference
23-Aug-2021
Dividend/Distribution - CYC
10-Aug-2021
Initial Director's Interest Notice
10-Aug-2021
CYC Board Changes
28-Jun-2021
Cyclopharm USFDA Update
7-Jun-2021
Ceasing to be a substantial holder from MUFG
4-Jun-2021
Ceasing to be a substantial holder from MS
4-Jun-2021
Becoming a substantial holder from MUFG
4-Jun-2021
Becoming a substantial holder from MS
3-Jun-2021
Ceasing to be a substantial holder from MUFG
2-Jun-2021
Ceasing to be a substantial holder from MS
1-Jun-2021
Becoming a substantial holder from MUFG
31-May-2021
Becoming a substantial holder from MS
26-May-2021
Ceasing to be a substantial holder from MUFG
25-May-2021
Ceasing to be a substantial holder from MS
24-May-2021
Becoming a substantial holder from MUFG
21-May-2021
Becoming a substantial holder from MS
20-May-2021
Ceasing to be a substantial holder from MUFG
20-May-2021
Ceasing to be a substantial holder from MS
19-May-2021
Becoming a substantial holder from MUFG
18-May-2021
Becoming a substantial holder from MS
18-May-2021
Ceasing to be a substantial holder from MUFG
18-May-2021
Ceasing to be a substantial holder from MS
13-May-2021
Becoming a substantial holder from MUFG
13-May-2021
Becoming a substantial holder from MS
11-May-2021
Ceasing to be a substantial holder from MUFG
10-May-2021
Ceasing to be a substantial holder from MS
7-May-2021
Becoming a substantial holder from MUFG
6-May-2021
Ceasing to be a substantial holder from MUFG
5-May-2021
Becoming a substantial holder from MS
4-May-2021
CYC Amended Constitution
4-May-2021
Results of Meeting
4-May-2021
Becoming a substantial holder from MUFG
4-May-2021
Ceasing to be a substantial holder from MUFG
4-May-2021
Managing Director's Address to Shareholders
4-May-2021
CYC 2021 AGM Presentation
4-May-2021
Chairman's Address to Shareholders
3-May-2021
Ceasing to be a substantial holder from MS
30-Apr-2021
Becoming a substantial holder from MS
29-Apr-2021
Ceasing to be a substantial holder from MS
20-Apr-2021
Becoming a substantial holder from MUFG
19-Apr-2021
Becoming a substantial holder from MS
19-Apr-2021
Ceasing to be a substantial holder from MUFG
16-Apr-2021
Ceasing to be a substantial holder from MS
15-Apr-2021
Becoming a substantial holder from MUFG
14-Apr-2021
Becoming a substantial holder from MS
30-Mar-2021
Notice of Annual General Meeting/Proxy Form
29-Mar-2021
Appendix 4G
26-Mar-2021
Change of Share Registry Details
12-Mar-2021
S&P DJI Announces March 2021 Quarterly Rebalance
12-Mar-2021
Confirmation of Technegas USFDA Timetable
8-Mar-2021
Change of Director's Interest Notice - DH
3-Mar-2021
Change of Director's Interest Notice - TM
3-Mar-2021
Date of Annual General Meeting
25-Feb-2021
Dividend/Distribution - CYC
24-Feb-2021
Change of Director's Interest Notice DH
24-Feb-2021
Change of Director's Interest Notice TM
19-Feb-2021
Appendix 2A LTIP
19-Feb-2021
Appendix 2A SPP
17-Feb-2021
Appendix 3B - Amended
17-Feb-2021
Cyclopharm Announces Results of Share Purchase Plan Offer
10-Feb-2021
Change in substantial holding - Chemical Overseas
10-Feb-2021
Change in substantial holding - Barings
8-Feb-2021
Change in substantial holding
4-Feb-2021
Change in substantial holding from CVC
3-Feb-2021
Change of substantial shareholding from AEF
1-Feb-2021
Share Purchase Plan Offer Booklet
1-Feb-2021
Appendix 2A - Placement
1-Feb-2021
Cleansing Notice - Share Purchase Plan
1-Feb-2021
Cleansing Notice - Placement
29-Jan-2021
Change in substantial holding
29-Jan-2021
Change in substantial shareholding from AEF
25-Jan-2021
Proposed issue of Securities - CYC
25-Jan-2021
Cyclopharm Capital Raising Presentation
25-Jan-2021
Cyclopharm Successfully Completes A$30 Million Placement
22-Jan-2021
SNMMI Requests USFDA to Expedite Approval For Technegas
21-Jan-2021
Trading Halt
14-Jan-2021
USFDA Approval Progress for Technegas and Business Update
26-Nov-2020
Bell Potter Healthcare Conference
22-Oct-2020
Change of Director's Interest Notice TM
1-Oct-2020
Change of Director's Interest Notice
29-Sep-2020
Change of Director's Interest Notice
23-Sep-2020
Cyclopharm Investor Presentation
15-Sep-2020
Technegas USA Trial Successfully Meets Primary Endpoint
9-Sep-2020
CYC Partners With McMasters University In COVID-19 Research
25-Aug-2020
Dividend/Distribution - CYC
27-Jul-2020
Change of Director's Interest Notice
27-Jul-2020
Appendix 2A
9-Jul-2020
Results of Meeting
9-Jul-2020
Managing Director's Address to Shareholders
9-Jul-2020
CYC 2020 AGM Presentation
9-Jul-2020
Chairman's Address to Shareholders
5-Jun-2020
Notice of Annual General Meeting/Proxy Form
29-May-2020
Technegas Approved in Russia - Clarification
27-May-2020
USFDA Approval to File Received for Technegas
26-May-2020
Technegas Approved in Russia
21-May-2020
Final share buy-back notice - Appendix 3F
6-May-2020
Form 484 cancellation of Long Term Incentive Plan shares
5-May-2020
Appendix 2A
14-Apr-2020
USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver
31-Mar-2020
CYC Appendix 4G
30-Mar-2020
Cyclopharm Lodges NDA for Technegas with the USFDA
24-Mar-2020
Cyclopharm Company Update
17-Mar-2020
Change of Director's Interest Notice
17-Mar-2020
Change of Director's Interest Notice
13-Mar-2020
Change of Director's Interest Notice
3-Mar-2020
Cyclopharm Investor Presentation
2-Mar-2020
Change of Director's Interest Notice
26-Feb-2020
Dividend/Distribution - CYC
15-Jan-2020
Change in substantial holding
15-Jan-2020
Change in substantial holding
13-Jan-2020
Change in substantial holding
3-Jan-2020
Becoming a substantial holder
2-Jan-2020
Change in substantial holding from CVC
2-Jan-2020
Change in substantial holding from AEF
31-Dec-2019
Becoming a substantial holder
31-Dec-2019
Appendix 3B
30-Dec-2019
Change of Director's Interest Notice
20-Dec-2019
CYC Institutional Placement - Premium To Share Price
20-Dec-2019
AGREEMENT TO UTILISE CYCLOTRON FACILITY ASSETS
19-Dec-2019
Trading Halt
19-Dec-2019
Pause in Trading
19-Dec-2019
Appendix 3B
12-Dec-2019
Change of Director's Interest Notice JM
12-Dec-2019
Appendix 3B
27-Nov-2019
Final Director's Interest Notice
27-Nov-2019
Board Update
21-Oct-2019
Cyclopharm Investor Presentation - TechKnow Invest Roadshow
30-Sep-2019
Cyclopharm Strengthens Leadership Team
22-Aug-2019
Dividend/Distribution - CYC
26-Jul-2019
Cyclopharm Investor Presentation - Bioshares 2019
27-Jun-2019
Change of Director's Interest Notice - TM
13-Jun-2019
Change of Director's Interest Notice - TM
31-May-2019
Appendix 3B LTIP
27-May-2019
Change of Director's Interest Notice
27-May-2019
Appendix 3B
21-May-2019
Announcement of buy-back - Appendix 3C
21-May-2019
Results of Meeting
21-May-2019
Managing Director's Address to Shareholders
21-May-2019
CYC 2019 AGM Presentation
21-May-2019
Chairman's Address to Shareholders
20-May-2019
Final share buy-back notice - Appendix 3F
18-Apr-2019
Notice of General Meeting/Proxy Form
4-Apr-2019
Cyclopharm Investor Presentation
3-Apr-2019
Change of Director's Interest Notice
29-Mar-2019
CYC Appendix 4G
29-Mar-2019
Annual Report to shareholders
27-Feb-2019
Dividend/Distribution - CYC
29-Oct-2018
CYC - FNN Interview
12-Oct-2018
Positive USFDA Meeting - Technegas sales expected in 2019
9-Oct-2018
CYC Form 484 Cancellation of Long Term Incentive Plan shares
17-Sep-2018
Change of Director's Interest Notice VG
17-Sep-2018
Response to ASX Appendix 3Y Query
12-Sep-2018
Change of Director's Interest Notice VG
4-Sep-2018
Cyclopharm FNN Investor Event
23-Aug-2018
Dividend/Distribution - CYC
13-Aug-2018
Change in substantial holding from CVC
10-Aug-2018
Change in substantial holding from AEF
2-Jul-2018
Appendix 3B LTIP
28-Jun-2018
Change of Director's Interest Notice
27-Jun-2018
Change of Director's Interest Notice - Amended
26-Jun-2018
Change of Director's Interest Notice
14-Jun-2018
Change in substantial holding from CVC
13-Jun-2018
Change in substantial holding from AEF
29-May-2018
Announcement of buy-back - Appendix 3C
29-May-2018
Results of Meeting
29-May-2018
CYC 2018 AGM Presentation
29-May-2018
Managing Director's Address to Shareholders
29-May-2018
Chairman's Address to Shareholders
28-May-2018
Final share buy-back notice - Appendix 3F
17-May-2018
Better Defining Airways Disease with Technegas
7-May-2018
Cyclopharm Acquires Scandinavian Distribution Business
27-Apr-2018
Notice of Annual General Meeting/Proxy Form
29-Mar-2018
40 Patient Milestone Achieved For Technegas USFDA Trial
26-Mar-2018
CYC Appendix 4G
15-Mar-2018
2017 Results Presentation
1-Mar-2018
Change of Director's Interest Notice - David Heaney
26-Feb-2018
Dividend/Distribution - CYC
21-Dec-2017
FNN Interview and Presentation
12-Dec-2017
Cyclopharm FNN Investor Event
20-Nov-2017
Change of Director's Interest Notice - D Heaney